Congratulations to Christoph Hagemeyer on his promotion

Congratulations to Associate Professor Christoph Hagemeyer, who has been promoted to Professor (Research)! The promotion is effective from 3 July.

The University Professorial Promotion Committee noted A/Prof Hagemeyer's "significant contribution to the University in the areas of academic activity: research, engagement and education. In particular, the Committee noted [his] contributions to leadership and strong translational work in [his] field."

A/Prof Hagemeyer was President of the Australian Society for Medical Research during 2020. See more about his research in the Australian Centre for Blood Diseases. Follow the group on their channels:

Antibody engineered to prevent clotting in stroke and heart attack

A/Prof Christoph Hagemeyer and Dr Erik Westein explain

the research to stop pathological blood clotting. See video

Monash researchers have invented an antibody which can prevent the formation of bad clots, such as those in stroke and heart attack.

Heart attack and stroke remain the leading causes of mortality and morbidity worldwide. Current anti-thrombotic (anti-clotting) therapies can, and do, cause severe bleeding complications because they also interfere with normal blood clotting. Four out of five patients who receive antiplatelet therapy still have recurring cardiovascular events.

Monash researchers in consortium granted $1million for lung disease research

A/Prof Christoph Hagemeyer and 

Dr Karen Alt

by Anne Crawford

Associate Professor Christoph Hagemeyer and Dr Karen Alt from the Australian Centre for Blood Diseases (ACBD) together with other researchers from Monash University, the University of Melbourne, the Alfred Hospital and Austin Health have been awarded $1 million* to conduct translational research into idiopathic pulmonary fibrosis (IPF).

IPF causes scar tissue (fibrosis) to build up in the lungs, progressively diminishing lung function and the transportation of oxygen into the bloodstream. The heterogeneous disease is progressive, fatal and incurable.

Smart nanomaterials to revolutionise insulin delivery for diabetes

Associate Professor Christoph Hagemeyer

by Anne Crawford

Type 1 diabetes (T1D), a disease with no cure, currently affects more than 120,000 Australians.

People with T1D are dependent on insulin, a hormone, to help keep their blood-sugar levels from skyrocketing which can lead to long-term complications such as kidney and heart diseases responsible for significant morbidity and mortality.

However, if too much insulin is injected, sugar levels become dangerously low, called hypoglycaemia, resulting in coma or death.

Associate Professor Christoph Hagemeyer, a research group leader in the Australian Centre for Blood Diseases (ACBD), has been granted $944,796 from the National Health and Medical Research Council (NHMRC) to further research that is generating smart nanoparticles that automatically regulate the optimal amount of insulin available to the body.

Monash researcher honoured by national advocacy role

Associate Professor Christoph Hagemeyer (left)
and outgoing ASMR president Dr Roger Yazbek.
Follow @cehagemeyer, @TheASMR1 

by Anne Crawford

Monash University’s Associate Professor Christoph Hagemeyer has been elected president of the Australia Society for Medical Research (ASMR), the peak professional body representing all national health and medical researchers.

A/Prof Hagemeyer, who heads the NanoBiotechnology Laboratory at the Australian Centre for Blood Diseases (ACBD), took over the presidency at the ASMR’s recent National Scientific Conference in Perth in November.

Spotlight on our NHMRC Fellowship winners: Associate Professor Christoph Hagemeyer

A/Professor Christopher Hagemeyer
ACBD, CCS.

by Anne Crawford

Associate Professor Christoph Hagemeyer. Senior Research Fellowship A (SFRA) to; develop smart targeted nanoparticles for diagnosis and therapy.  

Associate Professor Hagemeyer’s groundbreaking work in the emerging field of nanomedicine has been given a large boost with an NHMRC fellowship supporting him as a researcher for five years and also a ‘Translation Advancement Incentive’ to allow him to translate his research into clinical practice.